biostudies-literatureUnknown14(3)Kim DJBI Lilly Alliance<h4>Aims/introduction</h4>The EMPA-REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all-cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries.<h4>Materials and methods</h4>The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase-4 inhibitors (DPP-4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score-matched (1:1) 'as-treated' analyses comparing the risk of cardiovascular outcomes and all-cause mortality betJournal of diabetes investigation417-428https://www.ebi.ac.uk/biostudies/studies/S-EPMC9951576biostudies-literatureEmpagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.PMC9951576Lee SKim DJEMPRISE East Asia Study GroupHa KHNode KSeino YNangaku MYabe DDeruaz-Luyet AKyaw MHSheu WHChung WJLei WSaarelainen LYasui ATan ECfalseEmpagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.<h4>Aims/introduction</h4>The EMPA-REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all-cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program evaluates how these effects translate in a broad population of patients with type 2 diabetes in routine clinical care across countries.<h4>Materials and methods</h4>The study included patients ≥18 years with type 2 diabetes initiating empagliflozin or any dipeptidyl peptidase-4 inhibitors (DPP-4i) from large administrative databases in Japan, South Korea, and Taiwan. Propensity score-matched (1:1) 'as-treated' analyses comparing the risk of cardiovascular outcomes and all-cause mortality bet2023-01-01T00:00:00Z2023 Mar2025-04-22T03:33:03.476Z2025-04-05T20:46:13.691ZS-EPMC99515763671621210.1111/jdi.13959